Market Overview

A Look At All Of Pfizer's Acquisitions Over The Past 2 Years

Share:
A Look At All Of Pfizer's Acquisitions Over The Past 2 Years
Related PFE
Exclusive: Corium CEO Gives The Scoop On His Company's Latest Alzheimer's Data
Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns
Oakview Capital Management, L.p. Buys TripAdvisor Inc, Pfizer Inc, NetApp Inc, Sells Ralph ... (GuruFocus)

Pfizer Inc. (NYSE: PFE) is back on the M&A hunt, having agreed to acquire Anacor Pharmaceuticals Inc (NYSE: ANAC) for $5.2 billion.

Ironically, it is nearly two years to the day from when AstraZeneca plc (ADR) (NYSE: AZN) rejected Pfizer's final offer to acquire the company for £55 per share.

Here is a look at some of Pfizer's completed acquisitions over the past two years.

2014 Acquisitions

On July 16, Pfizer acquired InnoPharma, a pharmaceutical development company with 10 generic products, for $225 million upfront and up to $135 million in milestone payments. The transaction was completed on September 25, 2014.

On December 1, Pfizer reported the closing of Baxter's Marked Vaccines Portfolio for $635 million.

Related Link: Bull And Bear Takeaways From Pfizer's $5.2 Billion Deal

2015 Acquisitions

On January 5, Pfizer announced it has acquired a controlling interest in Redvax GmbH, a privately held Swiss pharmaceutical company. As part of the transaction, Pfizer gained access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.

On February 5, Pfizer announced it has agreed to acquire Hospira for $90 a share, or $17 billion. Pfizer said that the deal would be immediately accretive to its full year earnings following the close of the transaction by $0.10 to $0.12 per share. The deal was closed on September 3.

On May 11, Pfizer said that it acquired a minority interest in AM-Pharma for $87.5 million upfront and up to $512.5 million in future payments. AM-Pharma biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases.

Various media sources reported in late October that Pfizer was eyeing an acquisition of Allergan plc Ordinary Shares (NYSE: AGN). A deal was announced on November 23 in which Pfizer would acquire Allergan for $160 billion. However, the deal was officially terminated on April 6, 2016 due to new measures by the U.S. Treasury to cut down on inversion-style acquisitions.

Related Link: Pfizer Announces Merger Termination With Allergan; Will Pay $150 Million Breakup Fee

2016 Acquisitions

On January 13, Pfizer announced it has acquired Treerly and its family of Treerly products. Treerly is a China-based healthcare brand that focuses on nutritional healthcare needs for women.

On May 5, Reuters and other news sources reported that Pfizer has approached Medivation Inc (NASDAQ: MDVN) over a potential acquisition. A formal offer has not been disclosed.

Posted-In: AM-Pharma Baxter's Marked VaccinesBiotech Long Ideas Health Care M&A Trading Ideas General Best of Benzinga

 

Related Articles (AGN + ANAC)

View Comments and Join the Discussion!